Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
This test measures the activity of factor XI, a clotting protein made in the liver that helps your blood form stable clots after an injury. It is one part of the coagulation cascade, a series of steps that work together to stop bleeding. The result reflects how well factor XI is functioning in your plasma using a clot-based assay.
Your provider may see this reported as an activity level. The method involves mixing your plasma with standardized reagents to observe clot formation, which indicates whether factor XI is working as expected.
Checking factor XI can help explain a prolonged activated partial thromboplastin time, easy bruising, nosebleeds, heavy menstrual bleeding, or bleeding after dental work or surgery. It can also help plan procedures if you have a personal or family history of bleeding, and it is sometimes used when there is concern for an inhibitor that interferes with factor function.
Low factor XI activity can point to an inherited or acquired deficiency, which often causes bleeding mainly with trauma or procedures rather than spontaneous joint or muscle bleeds. In contrast, higher than expected activity has been linked in some studies to a higher tendency to form clots, so context matters. Your result is interpreted alongside your history, examination, other coagulation tests, and medications.
If your factor XI activity is below the laboratory’s reference interval, your clinician may consider inherited deficiency, liver disease, disseminated intravascular coagulation, or an acquired inhibitor. Repeat testing, a mixing study, and related tests such as prothrombin time, activated partial thromboplastin time, and levels of other clotting factors can help narrow the cause. If a lifelong pattern is suspected, genetic testing for changes in the F11 gene may be discussed.
If your activity is within the expected interval and you still have bleeding symptoms, your care team may look for other causes such as platelet disorders or von Willebrand disease. If activity is above the expected interval, your clinician will interpret this carefully in light of your medications and overall risk. Always tell your provider about any anticoagulants or supplements you take, any recent illness, and any prior bleeding with procedures so your results can be interpreted accurately.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Underfilling the blue-top citrate tube or drawing through a heparinized line can falsely lower or alter factor XI activity. A proper clean venipuncture and correct blood to anticoagulant ratio are important for accurate results.
Heparin, warfarin, and direct oral anticoagulants can interfere with clot-based factor assays. Emerging factor XI inhibitors and high-dose antiplatelet therapy may also affect results or clinical interpretation. Always provide a complete medication list.
Factor XI is synthesized in the liver, so liver disease can reduce activity. Conditions that consume clotting factors, such as disseminated intravascular coagulation, may also lower measured activity and should be considered in acutely ill patients.
Clotted samples, significant hemolysis, lipemia, or delays in processing can produce unreliable values. Prompt centrifugation and testing of properly handled platelet-poor plasma improve accuracy.
Congenital factor XI deficiency can range from mild to severe and may be more common in certain families or ancestries. Bleeding often occurs with surgery or dental work, so family and procedural histories are valuable.
Physiologic changes in pregnancy and use of estrogen-containing therapies can alter coagulation test results. Your clinician may use pregnancy-adjusted interpretation and consider timing relative to delivery or hormonal therapy.
References